Recall events
/
Event 70444
Event summary
Timeline bucket January 25, 2015
Product types Drug
Classifications Class I
Statuses Terminated
Recalling firm wording Detox Transforms
Dossier provenance
Source snapshots represented here
openFDA Drug Enforcement
Report-date coverage
June 20, 2012–July 08, 2026
Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.
Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.
How coverage and grouping work
Device root-cause evidence is not applicable to this event.
No grouped product has the official product type device; this is not an unavailable-enrichment finding.
Complete imported group
Every recalled product in this event
5 official enforcement rows
Product dates, classifications, firms, and source wording remain attached to their individual rows.
Opening this dossier never hides products that did not match a prior timeline filter.
drug · product 1 of 5
EDGE Amplified Weight Release capsules, 400 mg, 60-count bottle, Developed by Signature, 1027 Highway 70 W, Suite 227, Garner, NC 27529, UPC 8 52175 00417 4.
D-0977-2015
Recall number D-0977-2015
Initiated January 25, 2015
Classification Class I
Status Terminated
Quantity 150 bottles
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared phenolphthalein and fluoxetine, making EDGE an unapproved drug.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared phenolphthalein and fluoxetine, making EDGE an unapproved drug.
Code information Lots: ALL
Distribution pattern WV who distributed Nationwide.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[2255]
FDA event record
· Exact recall-number query on openFDA
drug · product 2 of 5
iNDiGO capsules, 220 mg, 60-count bottle, Developed by Signature, 1027 Highway 70 W, Suite 227, Garner, NC 27529, UPC 8 52175 00404 4.
D-0978-2015
Recall number D-0978-2015
Initiated January 25, 2015
Classification Class I
Status Terminated
Quantity 175 bottles
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared phenolphthalein, making iNDiGO an unapproved drug.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared phenolphthalein, making iNDiGO an unapproved drug.
Code information Lot: 000034, Exp 04/10/17
Distribution pattern WV who distributed Nationwide.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[2118]
FDA event record
· Exact recall-number query on openFDA
drug · product 3 of 5
AMPD GOLD Bee Pollen capsules, 350 mg, 60-count bottle, Signature, 1027 Highway 70 W, Suite 227, Garner, NC 27529, UPC 8 52175 00418 1.
D-0979-2015
Recall number D-0979-2015
Initiated January 25, 2015
Classification Class I
Status Terminated
Quantity 150 bottles
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared sildenafil, making AMPD GOLD an unapproved drug.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared sildenafil, making AMPD GOLD an unapproved drug.
Code information Lots: ALL
Distribution pattern WV who distributed Nationwide.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[4392]
FDA event record
· Exact recall-number query on openFDA
drug · product 4 of 5
BtRiM Max capsules, 60-count bottle, Developed by Signature, 1027 Highway 70 W, Suite 227, Garner, NC 27529, UPC 8 52175 00406 8.
D-0980-2015
Recall number D-0980-2015
Initiated January 25, 2015
Classification Class I
Status Terminated
Quantity 173 bottles
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared phenolphthalein, making BtRiM Max an unapproved drug.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared phenolphthalein, making BtRiM Max an unapproved drug.
Code information Lot: 00002, Exp 04/27/17
Distribution pattern WV who distributed Nationwide.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[4390]
FDA event record
· Exact recall-number query on openFDA
drug · product 5 of 5
iNSANE Bee Pollen capsules, 200 mg, 60-count bottle, Developed by Signature, 1027 Highway 70 W, Suite 227, Garner, NC 27529, UPC 8 52175 00408 2.
D-0981-2015
Recall number D-0981-2015
Initiated January 25, 2015
Classification Class I
Status Terminated
Quantity 200 bottles
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared phenolphthalein and fluoxetine, making iNSANE an unapproved drug.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared phenolphthalein and fluoxetine, making iNSANE an unapproved drug.
Code information Lot: 0000:02, Exp 06/20/17
Distribution pattern WV who distributed Nationwide.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[4439]
FDA event record
· Exact recall-number query on openFDA
